CP 422935

Drug Profile

CP 422935

Alternative Names: NGD 951

Latest Information Update: 04 Aug 2009

Price : $50

At a glance

  • Originator Neurogen Corporation
  • Developer Neurogen Corporation; Pfizer
  • Class Anorectics
  • Mechanism of Action Neuropeptide Y receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bulimia nervosa; Eating disorders; Obesity

Most Recent Events

  • 11 Jan 2001 Suspended-I for Bulimia nervosa in USA (PO)
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
  • 24 Dec 1997 Suspended-I for Eating disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top